Pharmacokinetic changes induced by focused ultrasound in glioma-bearing rats using dynamic contrast-enhanced MRI measurement.
Authors: Zhao YL, Xia X, Liang CE, Li XM
It has been shown that focused ultrasound (FUS) can be effectively used for brain tumor therapy, and as a noninvasive, targeted drug delivery technique combined with microbubbles. In this study, magnetic resonance imaging (MRI) was used to measure the kinetics of Gadolinium diethylenetriamine Penta acetic acid (Gd-DTPA) in glioma-bearing rats. Ten glioma-bearing rats (9-12 weeks, 290-340 g weight) were used in the study. After the use of dynamic contrast enhancement (DCE)-MRI, the spatial permeability of FUS-induced blood-brain barrier disruption (BBB-D) was evaluated, and the kinetic parameters by the general kinetic model (GKM) were calculated. The results show that mean trans K of the contralateral tumor was significantly lower than the mean trans K of sonicated tumor. Moreover, the transfer constant trans K in ultrasound tumors was closely related to tissue extravasation (R = 0.95), suggesting that DCE-MRI can determine drug accumulation in the brain. Except for a few small red blood cell extravasations, there was no macroscopic damage according to the histologic analysis. The study showed that the DCE-MRI can be a valuable tool in quantifying BBB permeability in tumors and monitor the kinetics of FUS-induced BBB-D processes.
Introduction
Purpose
Drug delivery with BBB opening
Study Objective
To determine how focused ultrasound alters pharmacokinetic parameters in glioma-bearing rats using dynamic contrast-enhanced MRI.
Animal model / Human subject
Rat (strain not reported, age not reported, sex not reported)
Disease model
glioma
MRI or image guidance method
MRI
Targeted brain region(s)
Tumors
Target coordinates
Not provided
Cargo name and characteristics
Gadolinium-based MRI contrast agent (small-molecule extracellular contrast agent, e.g., Gd-DTPA)
Route of administration
Intravenous
Outcomes and Safety
Summary of Outcomes
Focused ultrasound induced changes in tumor pharmacokinetics in glioma-bearing rats as detected by dynamic contrast-enhanced MRI; no specific FUS parameter settings were reported.
Duration of biological effect
not provvided
Safety-related matter
No safety concerns or adverse effects are mentioned in the provided text.
Brain Region
Ultrasound Parameters
Ultrasound instrument
not specified
FUS Frequency
not specified
FUS Intensity
not specified
FUS Pressure
not specified
FUS Mode
not specified
Pulse duration
not specified
Duration of a single FUS session
not specified
Focal Characteristics
not specified
Treatment frequency
not provided
We are open to feedback. If you see a mistake or have a suggestion, please contact us.
← Back to Search